The green day-ahead market (G-DAM) has a weighted average price of ₹4.07 per unit during the period under review.

ISB 2001 is a tri-specific antibody therapeutic for targeting BCMA and CD38 on myeloma cells, as well as CD3 on T cells.

Application error: a client-side exception has occurred (see the browser console for more information).

As per RBI’s latest data release, credit growth dipped sharply in April. From 10.9% YoY growth at the beginning of April, it ...

Tata Motors Limited announced that its board committee has nodded to an issue of non-convertible debentures (NCDs) worth up ...

The new capacity addition is part of UltraTech's strategic growth strategy to cater to growing cement demand in domestic as ...

The drug has been chosen as the sole ustekinumab by BCBSM, Florida Healthcare Plan, and other closed-door health systems.

The business reported a Net Interest Income (NII) registered a growth of 1.5% to ₹42,774 Crore versus ₹41,655 Crore in Q4FY24.

The license will enable Zaakpay to legally enable merchant payments via its web platform, which will enable it to further ...

Net profit for FY2025 increased 31% YoY at ₹1,521 crore. Total revenue for the year increased 20% YoY at ₹4,829 crore.

Mid cap stocks as a whole, delivered 6.40% in last one year. Out of 94 mid-cap stocks, only 4 stock gave more than 90% yoy, ...

Company's revenues during FY25 was at ₹5,983.74 crore driven by high volume of orders and robust demand across core segments.